Screener
Spyre Therapeutics, Inc. SYRE Total Current Assets
Total Current Assets at other companies
Other financials
Where this comes from
Reported directly by Spyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AssetsCurrent.
The source filing: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 8:00 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001636282-26-000050
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Cash and cash equivalents | $97,185 | $85,721 |
| Marketable securities | 644,282 | 670,812 |
| Prepaid expenses and other current assets | 22,486 | 21,248 |
| Total current assets | 763,953 | 777,781 |
| TOTAL ASSETS | $763,953 | $777,781 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| CURRENT LIABILITIES | ||
| Accounts payable | $5,692 | $8,904 |
Item 1. Financial Statements (Unaudited).
FAQ
- What is Spyre Therapeutics, Inc.'s total current assets?
- Spyre Therapeutics, Inc. (SYRE) reported total current assets of $763.95M in Q1 2026.
- How has Spyre Therapeutics, Inc.'s total current assets changed year-over-year?
- Spyre Therapeutics, Inc.'s total current assets increased by 34.1% year-over-year, from $569.77M to $763.95M.
- What is the long-term trend for Spyre Therapeutics, Inc.'s total current assets?
- Over 5 years (2020 to 2025), Spyre Therapeutics, Inc.'s total current assets has grown at a 39.0% compound annual growth rate (CAGR), from $149.79M to $777.78M.
- What does total current assets mean?
- The sum of all assets expected to be converted to cash or consumed within one year — cash, receivables, inventory, and prepaid expenses.
Ask your AI about Spyre Therapeutics, Inc.'s total current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude